Two compounds that do not fit the other research categories. ARA-290 and PT-141 (bremelanotide).
These are grouped by exclusion rather than by shared mechanism. ARA-290 is an erythropoietin-derived peptide studied in neuropathic and inflammatory research contexts without the haematopoietic activity of EPO itself. PT-141 is a melanocortin receptor agonist. They share no pathway and should be read independently.Each compound page carries a specification block listing lot number, chromatographic purity, percentage of stated label claim, identity confirmation, analytical method and testing laboratory — or states plainly that the certificate is pending. We publish which it is rather than rounding up.All compounds in this category are supplied strictly for laboratory research use. They are not for human or veterinary use, not for consumption, and not approved by the FDA for any purpose.
Showing all 2 results
